- Home
- RFM vs AVTX Comparison
RFM vs AVTX Comparison
Compare RFM & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$18.99
Company Overview
Basic Information| Metric | RFM | AVTX |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RFM | AVTX |
|---|---|---|
| Price | $14.10 | $18.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $32.29 |
| AVG Volume (30 Days) | 20.7K | ★ 341.4K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.89 | $3.39 |
| 52 Week High | $16.41 | $20.72 |
Technical Indicators
Market Signals| Indicator | RFM | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 53.63 |
| Support Level | $14.02 | $17.18 |
| Resistance Level | $14.35 | $20.20 |
| Average True Range (ATR) | 0.11 | 1.60 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 35.62 | 59.35 |
Price Performance
Historical Comparison RFM
AVTX
About RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).